Literature DB >> 2967671

Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species.

N V Jacobus1, F P Tally.   

Abstract

The in vitro activity of trospectomycin (U-63366; 6'-n-propyl spectinomycin pentahydrate sulfate) was evaluated against 189 clinical isolates of the Bacteroides fragilis group and 65 Bacteroides species isolates. At less than or equal to 8 micrograms/ml, the activity of trospectomycin compared favorably with those of clindamycin and cefoxitin against B. fragilis, Bacteroides distasonis, and Bacteroides vulgatus, and there was no cross resistance to these three drugs among the strains of the B. fragilis group. All the Bacteroides species were susceptible to trospectomycin. The results of this in vitro study indicate that trospectomycin possesses excellent activity against Bacteroides species.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2967671      PMCID: PMC172225          DOI: 10.1128/AAC.32.4.584

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Susceptibility of anaerobes to cefoxitin and other cephalosporins.

Authors:  F P Tally; N V Jacobus; J G Bartlett; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  Susceptibility of anaerobic bacteria to beta-lactam antibiotics and beta-lactamase production.

Authors:  K E Aldridge; C V Sanders; A C Lewis; R L Marier
Journal:  J Med Microbiol       Date:  1983-02       Impact factor: 2.472

4.  Bacteroides bivius and Bacteroides disiens in obstetrical patients: clinical findings and antimicrobial susceptibilities.

Authors:  D R Snydman; F P Tally; R Knuppel; J Landrigan; S L Gorbach; J G Bartlett
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

5.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens.

Authors:  W J Martin; M Gardner; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1972-02       Impact factor: 5.191

7.  Susceptibility of the Bacteroides fragilis group in the United States in 1981.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K E Aldridge; T J Cleary; S M Finegold; G B Hill; P B Iannini; R V McCloskey; J P O'Keefe; C L Pierson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

8.  Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins.

Authors:  D F Busch; L A Kureshi; V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

  8 in total
  6 in total

1.  In vitro susceptibilities of oral pigmented Bacteroides species to trospectomycin and other selected antimicrobial agents.

Authors:  C C Johnson; M Wendeler; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Accumulation of trospectomycin by strains of Salmonella typhimurium, Escherichia coli and Haemophilus influenzae.

Authors:  S Wong; L Bryan
Journal:  Can J Infect Dis       Date:  1990

3.  Human safety and pharmacokinetics of a single intramuscular dose of a novel spectinomycin analog, trospectomycin (U-63,366F).

Authors:  E Novak; L M Paxton; A Bye; R Patel; G E Zurenko; S F Francom
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  In vitro activity of trospectomycin (U-63366F), a novel spectinomycin analog, against gram-positive isolates from cancer patients.

Authors:  K Rolston; D H Ho; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

6.  Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.

Authors:  K Vogt; A C Rodloff; H Hahn
Journal:  Infection       Date:  1991 May-Jun       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.